Thumbnail
Access Restriction
Open

Author José, Pérez-garcía ♦ Cortés, Javier
Source PubMed Central
Content type Text
Publisher BioMed Central
File Format PDF
Date Created 2013-09-09
Copyright Year ©2012
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health ♦ Diseases
Subject Keyword Medicine(all)
Abstract The current understanding of the molecular biology of breast cancer presents an extremely complex portrait of the disease. Based on this knowledge, considerable efforts are being made to identify biomarkers that will predict the response to a specific treatment while minimizing the risk of unnecessary side effects. In breast cancer, the Ki67 index has been associated with poor prognosis and might play a relevant role in predicting benefit from adjuvant docetaxel, as observed in the article accompanying this editorial. Taxanes are one of the most active cytotoxic agents for breast cancer. However, the role of taxane-based chemotherapy as adjuvant treatment of early breast cancer remains controversial in some subsets of patients. For this reason, the Ki67 index might help to better define the group of patients who could have the optimal benefit.
ISSN 14655411
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2012-01-01
Rights Holder BioMed Central
e-ISSN 1465542X
Journal Breast Cancer Research : BCR
Volume Number 14
Issue Number 1
Starting Page 104


Open content in new tab

   Open content in new tab
Source: PubMed Central